Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Is gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?

Is gefitinib beneficial when combined with chemotherapy in the treatment of non-small cell lung cancer?

Posted by on Sep 8, 2020 in Lung cancer | 0 comments

In a nutshell This article looked at the effectiveness of gefitinib (Iressa) combined with chemotherapy when compared to a chemotherapy aline in the treatment of non-small cell lung cancer (NSCLC). The authors found that the addition of gefitinib to a chemotherapy increased the progression-free survival (PFS) of these...

Read More

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Searching for patients with stage III non-small cell lung cancer to trial a biological treatment.

Posted by on Sep 6, 2020 in Lung cancer | 0 comments

In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....

Read More

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...

Read More

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Looking for patients with metastatic non-small cell lung cancer to trial a biological treatment combination

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess the effectiveness of atezolizumab (Tecentriq) in combination with cabozantinib (Cabometyx) versus docetaxel (Taxotere) in patients with metastatic non-small cell lung cancer (NSCLC) which has previously been treated with immunotherapy and platinum-based chemotherapy....

Read More

Looking for patients with metastatic lung cancer to trial a treatment combination

Looking for patients with metastatic lung cancer to trial a treatment combination

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess whether osimertinib (Tagrisso) should be used alone or with chemotherapy for lung cancer and abnormalities (mutations) in the EGFR gene. The main outcome that will be measured in this trial is survival without progression of the disease. This trial will take place in New Jersey and New...

Read More

Looking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy

Looking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy

Posted by on Aug 23, 2020 in Lung cancer | 0 comments

In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...

Read More

Anlotinib as a third- or further-line therapy for patients with non-small cell lung cancer.

Anlotinib as a third- or further-line therapy for patients with non-small cell lung cancer.

Posted by on Aug 20, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of anlotinib (AL3818) on different subtypes of non-small cell lung cancer (NSCLC). The trial demonstrated that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with adenocarcinoma (ACC) and tended to improve survival in...

Read More

Evaluating patient-reported outcomes in the treatment of metastatic non-small-cell lung cancer with pembrolizumab plus pemetrexed–platinum

Evaluating patient-reported outcomes in the treatment of metastatic non-small-cell lung cancer with pembrolizumab plus pemetrexed–platinum

Posted by on Aug 15, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated treatment outcomes reported by patients with metastatic non-small-cell lung cancer (mNSCLC) who were treated by pembrolizumab (Keytruda) and pemetrexed (Alimta) and platinum chemotherapy. The authors found that adding pembrolizumab to pemetrexed-platinum chemotherapy improved health-related quality of life (HRQOL)...

Read More

Looking for patients with untreated extensive-stage small cell lung cancer to trial a immunotherapy combination

Looking for patients with untreated extensive-stage small cell lung cancer to trial a immunotherapy combination

Posted by on Aug 15, 2020 in Lung cancer | 0 comments

In a nutshell This trial is examining the effectiveness of atezolizumab (Tecentriq) plus carboplatin (Paraplatin) and etoposide (Etopophos) with or without tiragolumab in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The main outcomes that will be measured are progression-free survival (PFS) and overall survival...

Read More

COVID-19 with Cancer

COVID-19 with Cancer

Posted by on Jul 31, 2020 in Blog, Breast cancer, Colorectal cancer, Coronavirus / COVID-19, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...

Read More